Engineered cell therapy is designed to improve the ability of a patient's immune system to fight cancer by reintroducing improved immune cells. They are manufactured by collecting specific immune cells, called T cells, from the blood of the patient.
The global Engineered Cell Therapy market was valued at US$ 4230 million in 2023 and is anticipated to reach US$ 10580 million by 2030, witnessing a CAGR of 14.0% during the forecast period 2024-2030.
North American market for Engineered Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Engineered Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Engineered Cell Therapy in Research Institutes is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Engineered Cell Therapy include Medtronic, Stryker, Zimmer Inc., Acelity, Allergan, Cook Medical, Baxter International, Organovo Holdings Inc and Integra LifeSciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Engineered Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Engineered Cell Therapy.
Report Scope
The Engineered Cell Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Engineered Cell Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Engineered Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Medtronic
Stryker
Zimmer Inc.
Acelity
Allergan
Cook Medical
Baxter International
Organovo Holdings Inc
Integra LifeSciences
DePuy Synthes
B. Braun Melsungen AG
AbbVie
Becton
Dickinson and Company
Organogenesis Inc.
Athersys Inc.
ReproCell Inc.
RTI Surgical Inc.
Tissue Regenix Group Plc
RepliCel.
Segment by Type
Synthetic
Biologically Derived
Others
Segment by Application
Research Institutes
Biotechnological Organizations
Diagnostic Centres
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Engineered Cell Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Engineered Cell Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Synthetic
1.2.3 Biologically Derived
1.2.4 Others
1.3 Market by Application
1.3.1 Global Engineered Cell Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Research Institutes
1.3.3 Biotechnological Organizations
1.3.4 Diagnostic Centres
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Engineered Cell Therapy Market Perspective (2019-2030)
2.2 Engineered Cell Therapy Growth Trends by Region
2.2.1 Global Engineered Cell Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Engineered Cell Therapy Historic Market Size by Region (2019-2024)
2.2.3 Engineered Cell Therapy Forecasted Market Size by Region (2025-2030)
2.3 Engineered Cell Therapy Market Dynamics
2.3.1 Engineered Cell Therapy Industry Trends
2.3.2 Engineered Cell Therapy Market Drivers
2.3.3 Engineered Cell Therapy Market Challenges
2.3.4 Engineered Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Engineered Cell Therapy Players by Revenue
3.1.1 Global Top Engineered Cell Therapy Players by Revenue (2019-2024)
3.1.2 Global Engineered Cell Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Engineered Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Engineered Cell Therapy Revenue
3.4 Global Engineered Cell Therapy Market Concentration Ratio
3.4.1 Global Engineered Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Engineered Cell Therapy Revenue in 2023
3.5 Engineered Cell Therapy Key Players Head office and Area Served
3.6 Key Players Engineered Cell Therapy Product Solution and Service
3.7 Date of Enter into Engineered Cell Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Engineered Cell Therapy Breakdown Data by Type
4.1 Global Engineered Cell Therapy Historic Market Size by Type (2019-2024)
4.2 Global Engineered Cell Therapy Forecasted Market Size by Type (2025-2030)
5 Engineered Cell Therapy Breakdown Data by Application
5.1 Global Engineered Cell Therapy Historic Market Size by Application (2019-2024)
5.2 Global Engineered Cell Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Engineered Cell Therapy Market Size (2019-2030)
6.2 North America Engineered Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Engineered Cell Therapy Market Size by Country (2019-2024)
6.4 North America Engineered Cell Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Engineered Cell Therapy Market Size (2019-2030)
7.2 Europe Engineered Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Engineered Cell Therapy Market Size by Country (2019-2024)
7.4 Europe Engineered Cell Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Engineered Cell Therapy Market Size (2019-2030)
8.2 Asia-Pacific Engineered Cell Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Engineered Cell Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Engineered Cell Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Engineered Cell Therapy Market Size (2019-2030)
9.2 Latin America Engineered Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Engineered Cell Therapy Market Size by Country (2019-2024)
9.4 Latin America Engineered Cell Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Engineered Cell Therapy Market Size (2019-2030)
10.2 Middle East & Africa Engineered Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Engineered Cell Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Engineered Cell Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medtronic
11.1.1 Medtronic Company Detail
11.1.2 Medtronic Business Overview
11.1.3 Medtronic Engineered Cell Therapy Introduction
11.1.4 Medtronic Revenue in Engineered Cell Therapy Business (2019-2024)
11.1.5 Medtronic Recent Development
11.2 Stryker
11.2.1 Stryker Company Detail
11.2.2 Stryker Business Overview
11.2.3 Stryker Engineered Cell Therapy Introduction
11.2.4 Stryker Revenue in Engineered Cell Therapy Business (2019-2024)
11.2.5 Stryker Recent Development
11.3 Zimmer Inc.
11.3.1 Zimmer Inc. Company Detail
11.3.2 Zimmer Inc. Business Overview
11.3.3 Zimmer Inc. Engineered Cell Therapy Introduction
11.3.4 Zimmer Inc. Revenue in Engineered Cell Therapy Business (2019-2024)
11.3.5 Zimmer Inc. Recent Development
11.4 Acelity
11.4.1 Acelity Company Detail
11.4.2 Acelity Business Overview
11.4.3 Acelity Engineered Cell Therapy Introduction
11.4.4 Acelity Revenue in Engineered Cell Therapy Business (2019-2024)
11.4.5 Acelity Recent Development
11.5 Allergan
11.5.1 Allergan Company Detail
11.5.2 Allergan Business Overview
11.5.3 Allergan Engineered Cell Therapy Introduction
11.5.4 Allergan Revenue in Engineered Cell Therapy Business (2019-2024)
11.5.5 Allergan Recent Development
11.6 Cook Medical
11.6.1 Cook Medical Company Detail
11.6.2 Cook Medical Business Overview
11.6.3 Cook Medical Engineered Cell Therapy Introduction
11.6.4 Cook Medical Revenue in Engineered Cell Therapy Business (2019-2024)
11.6.5 Cook Medical Recent Development
11.7 Baxter International
11.7.1 Baxter International Company Detail
11.7.2 Baxter International Business Overview
11.7.3 Baxter International Engineered Cell Therapy Introduction
11.7.4 Baxter International Revenue in Engineered Cell Therapy Business (2019-2024)
11.7.5 Baxter International Recent Development
11.8 Organovo Holdings Inc
11.8.1 Organovo Holdings Inc Company Detail
11.8.2 Organovo Holdings Inc Business Overview
11.8.3 Organovo Holdings Inc Engineered Cell Therapy Introduction
11.8.4 Organovo Holdings Inc Revenue in Engineered Cell Therapy Business (2019-2024)
11.8.5 Organovo Holdings Inc Recent Development
11.9 Integra LifeSciences
11.9.1 Integra LifeSciences Company Detail
11.9.2 Integra LifeSciences Business Overview
11.9.3 Integra LifeSciences Engineered Cell Therapy Introduction
11.9.4 Integra LifeSciences Revenue in Engineered Cell Therapy Business (2019-2024)
11.9.5 Integra LifeSciences Recent Development
11.10 DePuy Synthes
11.10.1 DePuy Synthes Company Detail
11.10.2 DePuy Synthes Business Overview
11.10.3 DePuy Synthes Engineered Cell Therapy Introduction
11.10.4 DePuy Synthes Revenue in Engineered Cell Therapy Business (2019-2024)
11.10.5 DePuy Synthes Recent Development
11.11 B. Braun Melsungen AG
11.11.1 B. Braun Melsungen AG Company Detail
11.11.2 B. Braun Melsungen AG Business Overview
11.11.3 B. Braun Melsungen AG Engineered Cell Therapy Introduction
11.11.4 B. Braun Melsungen AG Revenue in Engineered Cell Therapy Business (2019-2024)
11.11.5 B. Braun Melsungen AG Recent Development
11.12 AbbVie
11.12.1 AbbVie Company Detail
11.12.2 AbbVie Business Overview
11.12.3 AbbVie Engineered Cell Therapy Introduction
11.12.4 AbbVie Revenue in Engineered Cell Therapy Business (2019-2024)
11.12.5 AbbVie Recent Development
11.13 Becton
11.13.1 Becton Company Detail
11.13.2 Becton Business Overview
11.13.3 Becton Engineered Cell Therapy Introduction
11.13.4 Becton Revenue in Engineered Cell Therapy Business (2019-2024)
11.13.5 Becton Recent Development
11.14 Dickinson and Company
11.14.1 Dickinson and Company Company Detail
11.14.2 Dickinson and Company Business Overview
11.14.3 Dickinson and Company Engineered Cell Therapy Introduction
11.14.4 Dickinson and Company Revenue in Engineered Cell Therapy Business (2019-2024)
11.14.5 Dickinson and Company Recent Development
11.15 Organogenesis Inc.
11.15.1 Organogenesis Inc. Company Detail
11.15.2 Organogenesis Inc. Business Overview
11.15.3 Organogenesis Inc. Engineered Cell Therapy Introduction
11.15.4 Organogenesis Inc. Revenue in Engineered Cell Therapy Business (2019-2024)
11.15.5 Organogenesis Inc. Recent Development
11.16 Athersys Inc.
11.16.1 Athersys Inc. Company Detail
11.16.2 Athersys Inc. Business Overview
11.16.3 Athersys Inc. Engineered Cell Therapy Introduction
11.16.4 Athersys Inc. Revenue in Engineered Cell Therapy Business (2019-2024)
11.16.5 Athersys Inc. Recent Development
11.17 ReproCell Inc.
11.17.1 ReproCell Inc. Company Detail
11.17.2 ReproCell Inc. Business Overview
11.17.3 ReproCell Inc. Engineered Cell Therapy Introduction
11.17.4 ReproCell Inc. Revenue in Engineered Cell Therapy Business (2019-2024)
11.17.5 ReproCell Inc. Recent Development
11.18 RTI Surgical Inc.
11.18.1 RTI Surgical Inc. Company Detail
11.18.2 RTI Surgical Inc. Business Overview
11.18.3 RTI Surgical Inc. Engineered Cell Therapy Introduction
11.18.4 RTI Surgical Inc. Revenue in Engineered Cell Therapy Business (2019-2024)
11.18.5 RTI Surgical Inc. Recent Development
11.19 Tissue Regenix Group Plc
11.19.1 Tissue Regenix Group Plc Company Detail
11.19.2 Tissue Regenix Group Plc Business Overview
11.19.3 Tissue Regenix Group Plc Engineered Cell Therapy Introduction
11.19.4 Tissue Regenix Group Plc Revenue in Engineered Cell Therapy Business (2019-2024)
11.19.5 Tissue Regenix Group Plc Recent Development
11.20 RepliCel.
11.20.1 RepliCel. Company Detail
11.20.2 RepliCel. Business Overview
11.20.3 RepliCel. Engineered Cell Therapy Introduction
11.20.4 RepliCel. Revenue in Engineered Cell Therapy Business (2019-2024)
11.20.5 RepliCel. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Medtronic
Stryker
Zimmer Inc.
Acelity
Allergan
Cook Medical
Baxter International
Organovo Holdings Inc
Integra LifeSciences
DePuy Synthes
B. Braun Melsungen AG
AbbVie
Becton
Dickinson and Company
Organogenesis Inc.
Athersys Inc.
ReproCell Inc.
RTI Surgical Inc.
Tissue Regenix Group Plc
RepliCel.
听
听
*If Applicable.
